Assessing an Oral SERD, DZD3969 in Patients With Advanced ER+HER2- Breast Cancer (MU-LAN1)

Condition:   Breast Neoplasms Intervention:   Drug: DZD3969 Sponsor:   Dizal (Jiangsu) Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials